Details

Izvajanje izravnalnih ukrepov po Schengenski konvenciji v Republiki Sloveniji in v sosednjih državah : diplomsko delo
ID Merc, Zvonko (Author), ID Debelak, Slavko (Mentor) More about this mentor... This link opens in a new window

.pdfPDF - Presentation file, Download (605,19 KB)
MD5: 24A4964BF57AF9D2D504A7C1457DAE8E
PID: 20.500.12556/rul/0e5235cd-0fcd-4964-b4bc-82adb1619577

Language:Slovenian
Keywords:Schengenska konvencija, Evropska unija, izravnalni ukrepi, meddržavni sporazumi, diplomske naloge
Work type:Bachelor thesis/paper
Typology:2.11 - Undergraduate Thesis
Organization:FU - Faculty of Administration
Place of publishing:Ljubljana
Publisher:[Z. Merc]
Year:2011
Number of pages:VII, 61 str.
PID:20.500.12556/RUL-21789 This link opens in a new window
UDC:341.222(043.2)
COBISS.SI-ID:3671214 This link opens in a new window
Publication date in RUL:11.07.2014
Views:2747
Downloads:614
Metadata:XML DC-XML DC-RDF
:
MERC, Zvonko, 2011, Izvajanje izravnalnih ukrepov po Schengenski konvenciji v Republiki Sloveniji in v sosednjih državah : diplomsko delo [online]. Bachelor’s thesis. Ljubljana : Z. Merc. [Accessed 24 March 2025]. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=21789
Copy citation
Share:Bookmark and Share

Similar documents

Similar works from RUL:
  1. Pomen tumorskih matičnih celic in epitelno-mezenhimskega prehoda pri napredovanju nedrobnoceličnega raka pljuč
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Proučevanje izražanja gena za fosfatidiletanolamin-N-metiltransferazo v nedrobnoceličnem pljučnem rakavem tkivu
  4. Uporabnost imunohistokemičnega določanja mutacij receptorja za epidermalni rastni faktor pri raku pljuč
  5. Sladkorna bolezen in športna vadba
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back